Is Elevance Health stock a Buy, Sell or Hold?
Elevance Health stock has received a consensus rating of buy. The average rating score is and is based on 40 buy ratings, 15 hold ratings, and 0 sell ratings.What was the 52-week low for Elevance Health stock?
The low in the last 52 weeks of Elevance Health stock was 440.29. According to the current price, Elevance Health is 105.20% away from the 52-week low.What was the 52-week high for Elevance Health stock?
The high in the last 52 weeks of Elevance Health stock was 549.35. According to the current price, Elevance Health is 84.31% away from the 52-week high.What are analysts forecasts for Elevance Health stock?
The 55 analysts offering price forecasts for Elevance Health have a median target of 502.25, with a high estimate of 625.00 and a low estimate of 380.00. The median estimate represents a 92.22 difference from the last price of 463.17.Elevance Health Stock Snapshot
462.81
Bid
2,500.00
Bid Size
463.12
Ask
200.00
Ask Size
3/17/2023
Date
4:15 PM
Time
925,150.00
Volume
468.50
Prev. Close
468.44
Open
108.45 B
Market Cap
237.46 M
Number of Shares
460.88
Day Low
468.87
Day High
463.17
440.29
52 Week Low
549.35
52 Week High
463.17
1.20
Dividend Yield
17.50
P/E Ratio
99.60
Free Float in %
Elevance Health News More News
Elevance Health Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Elevance Health Analyst Data
Total Analysts: 55
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 380.00
Median: 502.25
Highest: 625.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Elevance Health Analyst Opinions
- All
- Buy
- Hold
- Sell
| 03/08/23 | Deutsche Bank | Maintained Buy | $571 | ||
| 02/23/23 | J.P. Morgan | Maintained Buy | $572 | ||
| 01/26/23 | RBC Capital Markets | Maintained Hold | $523 | ||
| 01/26/23 | SVB Leerink | Maintained Buy | $580 | ||
| 01/04/23 | Wells Fargo & Co | Maintained Buy | $609 | ||
| 11/10/22 | Mizuho | Maintained Buy | $575 | ||
| 10/21/22 | Deutsche Bank | Maintained Buy | $581 | ||
| 10/21/22 | Morgan Stanley | Maintained Hold | $500 | ||
| 09/09/22 | Bank of America Merrill Lynch | Upgraded to Buy | $575 | ||
| 08/22/22 | SVB Leerink | Upgraded to Buy | $580 | ||
| 07/28/22 | Wells Fargo & Co | Maintained Buy | $557 | ||
| 07/25/22 | Morgan Stanley | Maintained Hold | $485 | ||
| 07/22/22 | SVB Leerink | Maintained Hold | $490 | ||
| 06/22/22 | Morgan Stanley | Downgraded to Hold | $533 | ||
| 06/17/22 | Loop Capital | Maintained Buy | $550 | ||
| 05/27/22 | Bernstein | Maintained Buy | $596 | ||
| 05/25/22 | Wells Fargo & Co | Maintained Buy | $580 | ||
| 04/25/22 | BMO Capital Markets | Maintained Buy | $625 | ||
| 04/22/22 | Deutsche Bank | Maintained Buy | $574 | ||
| 04/21/22 | Morgan Stanley | Maintained Buy | $607 | ||
| 04/21/22 | Credit Suisse | Maintained Buy | $584 | ||
| 04/21/22 | Goldman Sachs | Maintained Buy | $605 | ||
| 04/21/22 | SVB Leerink | Maintained Hold | $555 | ||
| 03/29/22 | UBS | Maintained Buy | $541 | ||
| 03/15/22 | SVB Leerink | Maintained Hold | $483 | ||
| 02/07/22 | Argus Research Company | Maintained Buy | $500 | ||
| 01/28/22 | Morgan Stanley | Maintained Buy | $518 | ||
| 01/27/22 | SVB Leerink | Maintained Hold | $465 | ||
| 12/20/21 | Mizuho | Upgraded to Buy | $510 | ||
| 12/17/21 | Morgan Stanley | Maintained Buy | $561 | ||
| 10/29/21 | Mizuho | Maintained Hold | $450 | ||
| 10/25/21 | Wells Fargo & Co | Maintained Buy | $500 | ||
| 10/21/21 | Stephens Inc. | Maintained Buy | $475 | ||
| 10/21/21 | Morgan Stanley | Maintained Buy | $486 | ||
| 10/21/21 | Barclays Capital | Maintained Buy | $485 | ||
| 10/21/21 | RBC Capital Markets | Maintained Hold | $452 | ||
| 10/21/21 | Credit Suisse | Maintained Buy | $486 | ||
| 10/21/21 | SVB Leerink | Maintained Hold | $430 | ||
| 09/27/21 | SVB Leerink | Maintained Hold | $403 | ||
| 08/31/21 | Morgan Stanley | Maintained Buy | $468 | ||
| 07/22/21 | Mizuho | Maintained Hold | $385 | ||
| 07/22/21 | Jefferies & Company Inc. | Maintained Buy | $453 | ||
| 07/22/21 | Stephens Inc. | Maintained Buy | $440 | ||
| 07/22/21 | Barclays Capital | Maintained Buy | $450 | ||
| 07/22/21 | BMO Capital Markets | Maintained Buy | $465 | ||
| 07/22/21 | RBC Capital Markets | Maintained Hold | $408 | ||
| 07/09/21 | Seaport Global Securities | Maintained Buy | $430 | ||
| 07/02/21 | Morgan Stanley | Maintained Buy | $459 | ||
| 06/10/21 | RBC Capital Markets | Downgraded to Hold | |||
| 05/19/21 | Wells Fargo & Co | Maintained Buy | $460 |
Elevance Health Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 165,505 | 172,418 | 183,903 | 214,406 | 253,572 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | 1.20 % | 1.23 % | 1.36 % | - | - |
| EPS | - | - | 42.29 | 49.77 | 58.49 |
| P/E Ratio | 14.25 | 12.61 | 11.07 | 9.41 | 8.00 |
| EBIT | 10,293 | 11,444 | 13,061 | 15,115 | 17,049 |
| EBITDA | 11,671 | 12,784 | 14,253 | 14,615 | 16,410 |
| Net Profit | 7,669 | 8,561 | 9,632 | 11,124 | 12,074 |
| Net Profit Adjusted | - | - | - | 11,124 | 12,074 |
| Pre-Tax Profit | 9,550 | 10,702 | 12,125 | 13,802 | 15,588 |
| Net Profit (Adjusted) | 9,575 | 10,700 | 11,678 | - | - |
| EPS (Non-GAAP) ex. SOE | 31.36 | 35.69 | 38.71 | - | - |
| EPS (GAAP) | 30.53 | 34.69 | 40.39 | 46.46 | 55.44 |
| Gross Income | 36,687 | 39,443 | 34,647 | - | - |
| Cash Flow from Investing | -3,968 | -3,860 | -4,371 | -7,795 | -10,609 |
| Cash Flow from Operations | 8,001 | 9,642 | 11,081 | 13,646 | 15,179 |
| Cash Flow from Financing | -3,256 | -3,872 | -4,150 | -3,217 | -1,674 |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | 6,909 | 8,569 | 10,243 | 12,198 | 13,295 |
| Free Cash Flow per Share | 30.64 | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | 13,833 | 10,361 | 6,103 | 9,143 | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 1,433 | 1,445 | 1,438 | 1,448 | 1,884 |
| Selling, General & Admin. Exp. | 18,386 | 18,911 | 20,219 | 22,813 | 26,162 |
| Shareholder’s Equity | - | - | - | 55,509 | 58,809 |
| Total Assets | 107,853 | 113,333 | 120,857 | 136,974 | 146,622 |
|
Previous Quarter ending 12/31/22 |
Current Quarter | Next Quarter |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | - | 19 | 11 | 2 |
| Average Estimate | - | - | 8.836 USD | 42.292 USD | 49.765 USD |
| Year Ago | - | - | 8.040 USD | - | 42.292 USD |
| Publish Date | - | - | 7/26/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 17 | - | - | 19 | 18 |
| Average Estimate | 39,773 USD | - | - | 165,505 USD | 172,418 USD |
| Year Ago | 36,018 USD | - | - | 155,660 USD | 165,505 USD |
| Publish Date | 1/25/2023 | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Elevance Health Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Kendrick Charles Morgan JR | 03/08/2023 | 2,314.00 | 15,327.00 | 462.22 | Sell | No |
| BOUDREAUX GAIL | 03/01/2023 | 17,614.00 | 135,863.00 | 468.78 | Sell | No |
| Penczek Ronald W | 03/01/2023 | 380.00 | 2,882.00 | 468.78 | Sell | No |
| Gallina John E | 03/01/2023 | 4,650.00 | 63,725.00 | 468.78 | Sell | No |
| Haytaian Peter D | 03/01/2023 | 5,469.00 | 17,893.00 | 468.78 | Sell | No |
| Kendrick Charles Morgan JR | 03/01/2023 | 1,084.00 | 17,641.00 | 468.78 | Sell | No |
| MCCARTHY GLORIA M | 03/01/2023 | 5,430.00 | 66,533.00 | 468.78 | Sell | No |
| Norwood Felicia F | 03/01/2023 | 4,754.00 | 33,443.00 | 468.78 | Sell | No |
| BOUDREAUX GAIL | 02/28/2023 | 2,471.00 | 109,180.00 | 469.03 | Sell | No |
| Penczek Ronald W | 02/28/2023 | 64.00 | 1,853.00 | 469.03 | Sell | No |
| Gallina John E | 02/28/2023 | 587.00 | 55,594.00 | 469.03 | Sell | No |
| Haytaian Peter D | 02/28/2023 | 607.00 | 11,354.00 | 469.03 | Sell | No |
| Kendrick Charles Morgan JR | 02/28/2023 | 293.00 | 14,157.00 | 469.03 | Sell | No |
| MCCARTHY GLORIA M | 02/28/2023 | 617.00 | 60,114.00 | 469.03 | Sell | No |
| Norwood Felicia F | 02/28/2023 | 495.00 | 26,189.00 | 469.03 | Sell | No |
| Todt Blair Williams | 02/28/2023 | 372.00 | 7,911.00 | 469.03 | Sell | No |
| BOUDREAUX GAIL | 02/28/2023 | 35,875.00 | 153,477.00 | n/a | Buy | No |
| BOUDREAUX GAIL | 02/28/2023 | 8,422.00 | 117,602.00 | n/a | Buy | No |
| Penczek Ronald W | 02/28/2023 | 1,195.00 | 3,262.00 | n/a | Buy | No |
| Penczek Ronald W | 02/28/2023 | 214.00 | 2,067.00 | n/a | Buy | No |
| Gallina John E | 02/28/2023 | 9,716.00 | 68,375.00 | n/a | Buy | No |
| Gallina John E | 02/28/2023 | 3,065.00 | 58,659.00 | n/a | Buy | No |
| Haytaian Peter D | 02/28/2023 | 9,716.00 | 23,362.00 | n/a | Buy | No |
| Haytaian Peter D | 02/28/2023 | 2,292.00 | 13,646.00 | n/a | Buy | No |
| Kendrick Charles Morgan JR | 02/28/2023 | 2,542.00 | 18,725.00 | n/a | Buy | No |
Elevance Health Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Elevance Health Inc Registered Shs | 5.12 | 1.00 | USD |
| 2021 | Elevance Health Inc Registered Shs | 4.52 | 0.98 | USD |
| 2020 | Elevance Health Inc Registered Shs | 3.80 | 1.18 | USD |
| 2019 | Elevance Health Inc Registered Shs | 3.20 | 1.06 | USD |
| 2018 | Elevance Health Inc Registered Shs | 3.00 | 1.14 | USD |
| 2017 | Elevance Health Inc Registered Shs | 2.70 | 1.20 | USD |
| 2016 | Elevance Health Inc Registered Shs | 2.60 | 1.81 | USD |
| 2015 | Elevance Health Inc Registered Shs | 2.50 | 1.79 | USD |
| 2014 | Elevance Health Inc Registered Shs | 1.75 | 1.39 | USD |
| 2013 | Elevance Health Inc Registered Shs | 1.50 | 1.62 | USD |
| 2012 | Elevance Health Inc Registered Shs | 1.15 | 1.89 | USD |
| 2011 | Elevance Health Inc Registered Shs | 1.00 | 1.51 | USD |
| 2010 | Elevance Health Inc Registered Shs | - | - | USD |
| 2009 | Elevance Health Inc Registered Shs | - | - | USD |
| 2008 | Elevance Health Inc Registered Shs | - | - | USD |
| 2007 | Elevance Health Inc Registered Shs | - | - | USD |
| 2006 | Elevance Health Inc Registered Shs | - | - | USD |
| 2005 | Elevance Health Inc Registered Shs | - | - | USD |
| 2004 | Elevance Health Inc Registered Shs | - | - | USD |
| 2003 | Elevance Health Inc Registered Shs | - | - | USD |
| 2002 | Elevance Health Inc Registered Shs | - | - | USD |
| 2001 | Elevance Health Inc Registered Shs | - | - | USD |
| 2000 | Elevance Health Inc Registered Shs | - | - | USD |
| 1999 | Elevance Health Inc Registered Shs | - | - | USD |
*Yield of the Respective Date
Elevance Health Inc Registered Shs Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | - | Q1 2023 Earnings Release | 04/26/2023 |
| Annual General Meeting | - | Annual General Meeting | 05/10/2023 |
| Earnings Report | 8.836 USD | Q2 2023 Earnings Release | 07/26/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 11/01/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 01/31/2024 |
Elevance Health Inc Registered Shs Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Shareholders' Meeting | - | - | 05/18/2022 |
Elevance Health Profile
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Moody’s Daily Credit Risk Score
Elevance Health Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.60 |
| Vanguard Group, Inc. (Subfiler) | 8.62 |
| T. Rowe Price Associates, Inc. (Investment Management) | 5.36 |
| State Street Corp. | 4.64 |
| Wellington Management Co. LLP | 3.70 |
| Vanguard Total Stock Market Index Fund | 3.09 |
| BlackRock Fund Advisors | 2.69 |
| Vanguard 500 Index Fund | 2.34 |
| Capital Research & Management Co. (International Investors) | 2.31 |
| BlackRock Institutional Trust Co. NA | 2.26 |
| Fidelity Management & Research Co. LLC | 1.96 |
| Geode Capital Management LLC | 1.78 |
| Sanders Capital LLC | 1.63 |
| Baillie Gifford & Co. | 1.59 |
| Blackrock Group Ltd. (Subfiler) | 1.14 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Elevance Health Management
| Name | Job |
|---|---|
| Ronald William Penczek | Chief Accounting Officer & Controller |
| Gloria M. McCarthy | Chief Administrative Officer & Executive VP |
| Marcus D. Wilson | Chief Analytics Officer |
| John Edward Gallina | Chief Financial Officer & Executive Vice President |
| Shantanu Agrawal | Chief Health Officer |
| Blair W. Todt | Chief Legal Officer & Executive Vice President |
| Bill Beck | Chief Marketing Officer |
| Kyle Weber | Chief Strategy Officer |
| Morgan Kendrick | EVP & President-Commercial & Specialty Business |
| Felicia Farr Norwood | EVP & President-Government Business Division |
| Peter David Haytaian | Executive VP, President-Carelon & CarelonRX |
| Elizabeth E. Tallett | Independent Chairman |
| Ryan M. Schneider | Independent Director |
| Robert L. Dixon | Independent Director |
| Susan D. DeVore | Independent Director |
| Lewis Hay | Independent Director |
| R. Kerry Clark | Independent Director |
| Bahija Jallal | Independent Director |
| Antonio Fabio Neri | Independent Director |
| Deanna Dawnette Strable-Soethout | Independent Director |
| Ramiro G. Peru | Independent Director |
| Gail Koziara Boudreaux | President, Chief Executive Officer & Director |
| Jeff Plante | President-Advanced Analytics & Services |
| Scott Towers | President-Dental Business |
| Rajeev Ronanki | President-Digital Platforms |
| Bryony Winn | President-Health Solutions |
| Kathleen S. Kiefer | Secretary |
| Chris Rigg | Senior VP & CFO-Commercial & Specialty Business |
| Dorothy A. Coleman | Senior VP & CFO-Government Business Division |
| Dustin Wilcox | VP & Chief Information Security Officer |
| Stephen V. Tanal | Vice President-Investor Relations |
| Jill A. Becher | Vice President-Planning & Execution |